UK biotech hands off mid-stage C. dif­fi­cile drug in up to $570M deal

A biotech in the UK has out-li­censed a C. dif­fi­cile can­di­date to a US biotech for fur­ther clin­i­cal and com­mer­cial­iza­tion ef­forts.

UK-based Des­tiny Phar­ma an­nounced Fri­day that it is hand­ing NTCD-M3 to Se­bela Phar­ma­ceu­ti­cals. The deal in­cludes an ini­tial $1 mil­lion up­front, $19 mil­lion in de­vel­op­ment mile­stones, and an ad­di­tion­al $550 mil­lion in sales mile­stones — on top of roy­al­ties.

The deal al­lows Se­bela to lead and fi­nance clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion of the drug in North Amer­i­ca, while Des­tiny re­tains the ma­jor­i­ty of rights in Eu­rope and the rest of the world. Des­tiny added in a state­ment that Se­bela “has a mi­nor­i­ty in­ter­est in any in­come gen­er­at­ed in these non-North Amer­i­can ter­ri­to­ries based on the clin­i­cal stud­ies it is fund­ing.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER